Dexeryl cream Uses, Dosage, Side Effects &Warnings

dexeryl cream
0

dexeryl cream Generic drug of the therapeutic class: Dermatology

active principles: Glycerol (E422) , Vaseline , Paraffin

what is dexeryl cream ?

This medicine is recommended:

  • as an adjunctive treatment for skin dryness that accompanies certain skin conditions such as atopic dermatitis, ichthyotic conditions, psoriasis,
  • as an adjunct treatment for shallow burns in shallow areas.

what is dexeryl cream used for and indication?

  • Adjuvant treatment of dry skin conditions of certain dermatoses such as atopic dermatitis, ichthyotic states psoriasis.
  • adjunctive treatment of superficial burns low areas.

Dexeryl Dosage

Apply the cream in thin layer on the areas to be treated once or twice a day, or more if necessary.

Contraindications

Allergy to one of the constituents of the product.

Dexeryl How does it work?

  • SKIN PROTECTOR.
  • Emollient and moisturizing cream.

Dexeryl Side Effects

Due to the presence of propyl parahydroxybenzoate , rare skin reactions allergic eczema type and exceptionally, immediate reactions with urticaria.

Dexeryl Interactions

Allergy to one of the constituents of the product.

Dexeryl Warnings and Precautions

Hepatic insufficiency

In patients with severe hepatic insufficiency, liver enzymes should be monitored regularly during pantoprazole treatment, especially in long-term use. If hepatic enzymes are increased, treatment should be discontinued).

Therapeutic Association

In the case of therapeutic associations, it is necessary to follow the summaries of the product characteristics of the drugs involved.

Malignant gastric tumor

  • The symptomatic response to pantoprazole treatment may mask the symptoms of a malignant gastric tumor and delay its diagnosis. In the presence of any alarming symptom (eg significant involuntary weight loss, recurrent vomiting, dysphagia, haematemesis, anemia or melena), and when a gastric ulcer is suspected or present, a malignant condition should be ruled out.
  • Further examinations should be considered if the symptoms persist despite appropriate treatment.

Concomitant administration of HIV protease inhibitors

  • Concomitant administration of pantoprazole and HIV protease inhibitors, whose absorption depends on gastric pH, such as latazanavir, is not recommended as this may significantly reduce their bioavailability.

Influence on the absorption of vitamin B12

  • In patients with Zollinger-Ellison syndrome and other pathological hypersecretory conditions requiring long-term treatment, pantoprazole, like any gastric secretory inhibitor, may decrease the absorption of vitamin B12 (cyanocobalamin) by hypo- or achlorhydria. This should be considered in patients with reduced reserves or risk factors for decreased vitamin B12 absorption during long-term treatment or if clinical symptoms are observed.

Long-term treatment

  • In the context of long-term treatment, especially when its duration exceeds 1 year, patients should be monitored regularly.

Gastrointestinal bacterial infections

  • Eupantol treatment may lead to a slight increase in the risk of gastrointestinal infections caused by bacteria such as Salmonella, Campylobacter , or C.difficile.

hypomagnesemia

  • Severe hypomagnesemic cases have been reported in patients treated with proton pump inhibitors (PPIs) such as pantoprazole for at least three months and in most cases for one year. Hypomagnesemia can manifest as severe clinical signs such as fatigue, tetany, delirious flushes, convulsions, dizziness, ventricular arrhythmia, but it can start insidiously and go unnoticed. In most patients, hypomagnesemia improved after magnesium supplementation and IPP discontinuation.
  • In patients requiring prolonged therapy or when PPIs are combined with digoxin or with drugs that may induce hypomagnesaemia (eg diuretics), blood magnesium levels should be considered by health professionals before starting treatment with IPP and regularly during treatment.

Bone fracture

  • Proton pump inhibitors, particularly if they are used in high doses over a prolonged period (> 1 year), may moderately increase the risk of hip, wrist and vertebral fractures, mainly in elderly or elderly patients. in the presence of other identified risk factors. Observational studies suggest that proton pump inhibitors can increase the overall risk of fracture by 10-40%. This increase may be due in part to other risk factors. Patients at risk of osteoporosis should be managed according to the recommendations in force, and receive an appropriate intake of vitamin D and calcium.

Subacute cutaneous lupus erythematosus (LECS)

  • Proton pump inhibitors (PPIs) are associated with very occasional cases of LECS. If lesions develop, especially on sun-exposed skin areas, and if they are accompanied by arthralgia, the patient should consult a doctor promptly and the health care provider should consider stopping Eupantol. The occurrence of LECS after treatment with a proton pump inhibitor may increase the risk of LECS with other proton pump inhibitors.

Interference with laboratory tests

  • Increased levels of Chromogranin A (CgA) may interfere with tests performed for the exploration of neuroendocrine tumors. To avoid this interference, treatment with Eupantol should be discontinued at least 5 days before measuring the level of CgA (see section 5.1). If the levels of CgA and gastrin have not normalized after the initial measurement, the measurements should be repeated 14 days after discontinuation of proton pump inhibitor therapy.
  • Because of a significant and long-lasting inhibition of gastric secretion, pantoprazole may interfere with the absorption of other drugs, for which gastric pH is a determinant of their oral bioavailability, such as some azole antifungals, such as ketoconazole, litraconazole, posaconazole and other drugs such as lerlotinib.

HIV protease inhibitors

  • Concomitant administration of pantoprazole and HIV protease inhibitors, whose absorption depends on gastric pH, such as latazanavir, is not recommended as this may significantly reduce their bioavailability .
  • If combination of an HIV protease inhibitor and a proton pump inhibitor is considered essential, regular clinical monitoring (eg viral load monitoring) is recommended. The dose of 20 mg pantoprazole daily should not be exceeded. The inhibitory dosage of HIV protease could be adjusted.

Coumarin anticoagulants (phenprocoumon or warfarin)

  • The combination of pantoprazole with warfarin or phenprocoumon did not affect the pharmacokinetics of warfarin, phenprocoumon, or INR. However, cases of increases in INR and prothrombin time have been reported in patients receiving PPI and concomitant warfarin or phenprocoumon.
  • An increase in INR and prothrombin time may cause bleeding, potentially fatal. In patients treated concomitantly with pantoprazole and warfarin or phenprocoumon, monitoring of INR and prothrombin time is recommended.

methotrexate

  • Increased blood levels of methotrexate have been reported in some patients when concomitant use of high doses of methotrexate (eg 300 mg) and proton pump inhibitors is used. Therefore, in situations where high doses of methotrexate are used, such as in cancer and psoriasis, temporary discontinuation of pantoprazole should be considered.

Other interaction studies

  • Pantoprazole is extensively metabolized in the liver by the cytochrome P450 enzyme system. The main metabolic pathway is demethylation by CYP2C19 and other metabolic pathways include CYP3A4 oxidation.
  • No clinically significant interactions have been observed in specific studies including carbamazepine, diazepam, glibenclamide, nifedipine, and oral contraceptives of levonorgestrel and detinyl estradiol.
  • Interaction of pantoprazole with other drugs or compounds metabolized by the same enzyme system can not be ruled out.
  • The results of a series of interaction studies showed that pantaprozole did not influence the metabolism of active substances metabolized by CYP1A2 (such as caffeine, theophylline), CYP2C9 (such as piroxicam, diclofenac, naproxen), CYP2D6 (as metoprolol), CYP2E1 (such as ethanol). Pantoprazole does not interfere with the absorption of digoxin bound to P-glycoprotein.
  • There is no interaction with concomitantly administered antacids.
  • Interaction studies have been conducted on the concomitant administration of pantoprazole and various antibiotics (clarithromycin, metronidazole, amoxicillin). No clinically significant interactions have been shown.
  • Medicinal products that inhibit or induce CYP2C19:
  • CYP2C19 inhibitors such as fluvoxamine may increase systemic pantoprazole exposure. For patients taking long-term pantoprazole at high doses, or for patients with hepatic impairment, dose reduction may be considered.
  • Enzyme inducers affecting CYP2C19 and CYP3A4 such as rifampicin and St. John’s wort ( Hypericum perforatum ) can reduce the plasma levels of IPPs, which are metabolized by these enzyme systems.

Pregnancy

  • A moderate number of data in the pregnant woman (between 300 and 1000 pregnancies) did not reveal any malformative or toxic effects for the fetus or the newborn of Eupantol.
  • Studies in animals have shown reproductive toxicity .
  • As a precaution, it is best to avoid the use of euupantol during pregnancy.

feeding

  • Studies in animals have shown that pantoprazole passes into breast milk. There is insufficient evidence that pantoprazole is excreted in breast milk, but passage into human breast milk has been reported.
  • A risk for newborns / infants can not be ruled out. Therefore, the decision to discontinue breastfeeding or to discontinue Eupantol treatment should take into account the benefit of breastfeeding for the child and the benefit of Eupantol treatment for the woman.

Fertility

  • Studies in animals have not shown evidence of impaired fertility following the administration of pantoprazole.

Drive and use machines

Dexeryl and PREGNANCY / BREAST FEEDING / FERTILITY

Pregnancy

  • No effect is expected on pregnancy as systemic exposure to glycerol, petrolatum and paraffin is negligible. Dexeryl can be used during pregnancy.

Breastfeeding

  • Given the nature of the active ingredients, no risk is expected. It is only recommended not to apply Dexeryl on the breast during breastfeeding.

Fertility

  • No effect is expected on fertility because systemic exposure to glycerol, petrolatum and paraffin is negligible.

What happens if I overdose from Dexeryl ?

Not applicable.

What is  Forms and Composition ?

FORMS and PRESENTATIONS
  • Cream (creamy white):   50 g and 250 g tubes.
COMPOSITION
  p g
Glycerol 0.15 g
vaseline 0.08 g
Liquid paraffin 0.02 g
  • Excipients: glycerol monostearate, stearic acid, cyclomethicone 5, dimeticone, macrogol 600, trolamine, propyl parahydroxybenzoate (E216), purified water.
  • Excipient with known effect: propyl parahydroxybenzoate (E216).

NOT’s

Edrug-online contains comprehensive and detailed information about drugs available in the medical field, and is divided into four sections:

general information:

  • Includes a general description of the drug, its use, brand names, FAQs, and relevant news and articles

Additional information:

  • General explanation about dealing with the medicine: how to take the medicine, the doses and times of it, the start and duration of its effectiveness, the recommended diet during the period of taking the medicine, the method of storage and storage, recommendations in cases for forgetting the dose and instructions to stop taking the drug and take additional doses.

Special warnings:

  • For pregnant and breastfeeding women, the elderly, boys and drivers, and use before surgery.

Side effects:

  • It treats possible side effects and drug interactions that require attention and its effect on continuous use.
  • The information contained in this medicine is based on medical literature, but it is not a substitute for consulting a doctor.

Leave A Reply